Colonic_ischemia_complicating_immunotherapy_with_interleukin-2_and_interferon-alpha._Colonic_ischemia_(CI)_is_a_rare_complication_of_high-dose_interleukin-2_(IL-2)_immunotherapy._This_complication_occurred_in_three_of_141_patients_(2.1%)_with_metastatic_cancer_treated_with_high-dose_IL-2_therapy;_CI_only_developed_in_patients_receiving_interferon-alpha_(IFN)_with_IL-2_(three_of_21,_14%)_compared_with_none_of_120_in_those_patients_receiving_IL-2_alone_(P_equals_0.0009)._Severe_diarrhea_(greater_than_or_equal_to_7_bowel_movements/day)_also_was_significantly_more_common_in_patients_receiving_IFN_with_IL-2_(six_of_21,_29%)_than_in_those_receiving_IL-2_alone_(three_of_120,_2.5%,_P_equals_0.001)_and_preceded_the_clinical_diagnosis_of_CI_in_all_three_patients._Three_of_nine_patients_with_severe_diarrhea_had_CI._Hematochezia_occurred_in_four_patients,_all_of_whom_received_IFN_with_IL-2;_three_had_CI,_and_the_other_patient_had_nonspecific_colitis._Differences_in_vasopressor_use_did_not_explain_the_increased_risk_of_CI_in_patients_receiving_IFN;_those_receiving_IFN_with_IL-2_required_phenylephrine_less_often_than_patients_receiving_IL-2_alone_(P_equals_0.01)._The_administration_of_lymphokine-activated_killer_(LAK)_cells_had_no_significant_effect_on_the_incidence_of_CI,_severe_diarrhea,_peritonitis,_or_vasopressor_use;_two_of_three_patients_with_CI,_however,_had_their_ischemic_episode_within_24_hours_after_the_last_of_three_LAK_cell_infusions._In_conclusion,_CI_is_an_unusual_complication_of_high-dose_IL-2_and_IFN_immunotherapy._In_patients_receiving_such_combination_therapy,_severe_diarrhea_is_a_risk_factor_for_the_subsequent_occurrence_of_CI.